Ziprasidone mesylate - Generic Drug Details

What are the generic sources for ziprasidone mesylate and what is the scope of freedom to operate?

Ziprasidone mesylate is the generic ingredient in two branded drugs marketed by Viatris, Gland Pharma Ltd, and MSN, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

Seven suppliers are listed for this compound.

Summary for ziprasidone mesylate

US Patents:	0
Tradenames:	2
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	7
Raw Ingredient (Bulk) Api Vendors:	56
Clinical Trials:	1
Patent Applications:	285
What excipients (inactive ingredients) are in ziprasidone mesylate?	ziprasidone mesylate excipients list
DailyMed Link:	ziprasidone mesylate at DailyMed

Recent Clinical Trials for ziprasidone mesylate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Yang Fude	Phase 4
Pfizer	Phase 4

See all ziprasidone mesylate clinical trials

Pharmacology for ziprasidone mesylate

Drug Class

Atypical Antipsychotic

Anatomical Therapeutic Chemical (ATC) Classes for ziprasidone mesylate

N05AE	Indole derivatives
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for ziprasidone mesylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gland Pharma Ltd	ZIPRASIDONE MESYLATE	ziprasidone mesylate	POWDER;INTRAMUSCULAR	211908-001	Dec 26, 2019	AP	RX	No	No
Msn	ZIPRASIDONE MESYLATE	ziprasidone mesylate	POWDER;INTRAMUSCULAR	216091-001	Sep 15, 2022	AP	RX	No	No
Viatris	GEODON	ziprasidone mesylate	POWDER;INTRAMUSCULAR	020919-001	Jun 21, 2002	AP	RX	Yes	Yes

Expired US Patents for ziprasidone mesylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viatris	GEODON	ziprasidone mesylate	POWDER;INTRAMUSCULAR	020919-001	Jun 21, 2002
Viatris	GEODON	ziprasidone mesylate	POWDER;INTRAMUSCULAR	020919-001	Jun 21, 2002
Viatris	GEODON	ziprasidone mesylate	POWDER;INTRAMUSCULAR	020919-001	Jun 21, 2002
Viatris	GEODON	ziprasidone mesylate	POWDER;INTRAMUSCULAR	020919-001	Jun 21, 2002
Viatris	GEODON	ziprasidone mesylate	POWDER;INTRAMUSCULAR	020919-001	Jun 21, 2002
Viatris	GEODON	ziprasidone mesylate	POWDER;INTRAMUSCULAR	020919-001	Jun 21, 2002

Ziprasidone mesylate Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Ziprasidone Mesylate

Market Overview

Ziprasidone mesylate, commonly known by the brand name Geodon, is a second-generation atypical antipsychotic used primarily for the treatment of schizophrenia and bipolar disorder. The global market for ziprasidone mesylate is experiencing significant growth, driven by several key factors.

Drivers of Market Growth

Rising Cases of Mental Health Issues

The increasing prevalence of mental health disorders such as schizophrenia and bipolar disorder is a major driver of the ziprasidone market. As mental health awareness and diagnosis rates improve, the demand for effective treatments like ziprasidone mesylate is on the rise[1][3].

Effectiveness and Safety Profile

Ziprasidone mesylate is preferred due to its relatively lower side effects compared to other antipsychotics, particularly in terms of weight gain and cholesterol levels. It also offers effective control over psychosis and agitation with minimal sedation, making it a favorable option for patients[1].

Availability and Dosage Forms

The drug is available in both oral and intramuscular injection forms, providing flexibility for patients. Oral forms include capsules and a liquid suspension, while the intramuscular injection is used for acute agitation in schizophrenic patients[1][2].

Market Segmentation

Method Outlook

The market is segmented based on the method of administration, with oral forms and intramuscular injections being the primary categories. The oral segment is further divided into capsules and liquid suspensions, catering to different patient needs[1].

Application Outlook

The primary end-use sectors include hospitals, drug stores, and other healthcare facilities. Hospitals are a significant segment due to the frequent use of ziprasidone mesylate in inpatient settings[1].

Regional Outlook

The market is geographically segmented into North America, Europe, Asia Pacific, and Latin America. Emerging economies in the Asia Pacific region present lucrative opportunities due to increasing healthcare investments and access to healthcare services[1].

Competitive Landscape

The global ziprasidone mesylate market is highly competitive, with several key players operating at regional and global levels. These include Pfizer, Sandoz, Lupin Pharmaceuticals, Mylan Pharmaceuticals, Apotex, Dr. Reddy’s Laboratories, and others. These companies are engaging in various strategies such as R&D investments, partnerships, mergers and acquisitions, and collaborations to maintain their market position[1].

Financial Trajectory

Revenue Growth

The global ziprasidone mesylate market is expected to register rapid revenue growth over the forecast period, driven by the increasing demand for effective antipsychotic treatments. The market size was robust in 2021 and is anticipated to continue growing due to the rising cases of mental health disorders[1].

Market Size and Sales

The Geodon brand, which is the original formulation of ziprasidone mesylate, had U.S. sales of approximately $21.8 million for the twelve months ending in January 2020. The launch of generic versions, such as the one by Dr. Reddy’s Laboratories, is expected to further expand the market by making the drug more affordable and accessible[4].

Market Opportunities

Innovative Marketing and Patient-Centric Care

Companies can leverage innovative marketing campaigns to educate psychiatrists and healthcare providers about the benefits of ziprasidone mesylate. Additionally, developing extended-release formulations and integrating ziprasidone delivery with telemedicine services can enhance patient compliance and satisfaction[3].

Expanding Healthcare Infrastructure

Emerging economies offer significant opportunities due to their expanding healthcare infrastructure and increasing focus on mental health services. Companies can enhance their geographic reach and invest in patient-centric care models to capitalize on these opportunities[3].

Market Challenges

Regulatory Requirements and Side Effects

The market faces challenges such as stringent regulatory requirements and the potential side effects associated with ziprasidone mesylate, including QT prolongation, neuroleptic malignant syndrome, and severe cutaneous adverse reactions. Addressing these challenges requires strategic R&D investments and regulatory intelligence[2][3].

Competition from Alternative Medications

The market is also competitive, with alternative antipsychotic medications offering better efficacy profiles. This competition impacts the sales of ziprasidone mesylate, making it essential for companies to differentiate their products through innovative formulations and marketing strategies[3].

Key Statistics and Trends

• Market Size: The global ziprasidone mesylate market was significantly robust in 2021 and is expected to register rapid revenue growth over the forecast period[1].
• Growth Drivers: Rising cases of mental health disorders, effectiveness in treatment, and availability in various forms are key drivers of the market[1][3].
• Regional Growth: Emerging economies in the Asia Pacific region are expected to drive significant growth due to increasing healthcare investments and access to services[1].
• Competitive Landscape: The market is highly competitive, with key players engaging in various strategies to maintain their market position[1].

"Ziprasidone mesylate for injection is indicated for the treatment of acute agitation in schizophrenic adult patients for whom treatment with oral therapy is not appropriate and for whom rapid control of aggressive behavior is needed."[2]

Key Takeaways

• The global ziprasidone mesylate market is driven by the increasing prevalence of mental health disorders and the drug's effectiveness in treatment.
• The market is segmented based on method of administration, application, and region.
• Key players are adopting various strategies to maintain their market position.
• Emerging economies present significant opportunities for market growth.
• The market faces challenges such as regulatory requirements, side effects, and competition from alternative medications.

FAQs

What is ziprasidone mesylate used for?

Ziprasidone mesylate is used for the treatment of schizophrenia and bipolar disorder, as well as for the acute treatment of agitation in schizophrenic patients.

What are the different forms of ziprasidone mesylate?

Ziprasidone mesylate is available in oral forms (capsules and liquid suspension) and as an intramuscular injection.

What are the key drivers of the ziprasidone mesylate market?

The key drivers include the rising cases of mental health disorders, the drug's effectiveness in treatment, and its availability in various forms.

Who are the major players in the ziprasidone mesylate market?

Major players include Pfizer, Sandoz, Lupin Pharmaceuticals, Mylan Pharmaceuticals, Apotex, Dr. Reddy’s Laboratories, and others.

What are the challenges faced by the ziprasidone mesylate market?

The market faces challenges such as stringent regulatory requirements, potential side effects, and competition from alternative antipsychotic medications.

Sources

1. Reports and Data: Global Ziprasidone Market – Forecast to 2030.
2. DailyMed: ZIPRASIDONE MESYLATE injection, powder, lyophilized, for solution.
3. 360iResearch: Ziprasidone Drugs Market Size & Share 2025-2030.
4. Business Wire: Dr. Reddy's Laboratories announces the launch of Ziprasidone Mesylate for Injection in the U.S. Market.